PriceTargets.com logo

ImageneBio - IMA Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $26.50
  • Forecasted Upside: 290.86%
  • Number of Analysts: 5
  • Breakdown:
  • 2 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 1 Strong Buy Ratings
$6.78 As of 12/4/2025 05:00 PM ET
▲ +0.15 (2.26%)

This chart shows the closing price for IMA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New ImageneBio Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IMA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IMA

Analyst Price Target is $26.50
▲ +290.86% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for ImageneBio in the last 3 months. The average price target is $26.50, with a high forecast of $30.00 and a low forecast of $23.00. The average price target represents a 290.86% upside from the last price of $6.78.

This chart shows the closing price for IMA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 5 contributing investment analysts is to hold stock in ImageneBio. This rating changed within the last month from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/9/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/7/2025
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/5/2025
  • 1 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 1 sell ratings
Ratings as of
11/4/2025
  • 1 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 2 sell ratings
Ratings as of
12/4/2025

Latest Recommendations

  • 1 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/25/2025WedbushDowngradeNeutral ➝ Underperform
10/24/2025Leerink PartnrsUpgradeStrong-Buy
10/24/2025Leerink PartnersInitiated CoverageOutperform$30.00
10/22/2025Weiss RatingsInitiated CoverageSell (E-)
9/29/2025Zacks ResearchDowngradeStrong-Buy ➝ Hold
7/25/2025WedbushLower TargetNeutral ➝ Neutral$25.00 ➝ $23.00
12/23/2024WedbushReiterated RatingNeutral$24.00
11/11/2024HC WainwrightReiterated RatingBuy ➝ Buy$48.00 ➝ $48.00
11/7/2024WedbushReiterated RatingNeutral$24.00
8/12/2024HC WainwrightReiterated RatingBuy ➝ Buy$48.00 ➝ $48.00
5/29/2024WedbushDowngradeOutperform ➝ Neutral$96.00 ➝ $24.00
5/29/2024HC WainwrightLower TargetBuy ➝ Buy$132.00 ➝ $48.00
5/14/2024WedbushReiterated RatingOutperform ➝ Outperform$96.00
3/19/2024HC WainwrightReiterated RatingBuy ➝ Buy$132.00
3/12/2024WedbushReiterated RatingOutperform$96.00
1/19/2024WedbushReiterated RatingOutperform ➝ Outperform$96.00
1/19/2024HC WainwrightReiterated RatingBuy ➝ Buy$132.00
11/16/2023William BlairReiterated RatingOutperform
11/9/2023HC WainwrightLower TargetBuy ➝ Buy$216.00 ➝ $132.00
9/21/2023WedbushInitiated CoverageOutperform$132.00
8/7/2023HC WainwrightReiterated RatingBuy ➝ Buy$216.00
5/4/2023HC WainwrightReiterated RatingBuy$216.00
3/17/2023HC WainwrightReiterated RatingBuy$264.00
3/15/2023Credit Suisse GroupLower TargetOutperform$192.00 ➝ $156.00
11/29/2022Credit Suisse GroupLower TargetOutperform$216.00 ➝ $192.00
11/29/2022HC WainwrightLower TargetBuy$312.00 ➝ $264.00
11/8/2022Credit Suisse GroupLower TargetOutperform$240.00 ➝ $216.00
4/13/2022HC WainwrightBoost TargetBuy$300.00 ➝ $312.00
3/17/2022Credit Suisse GroupLower Target$324.00 ➝ $288.00
12/23/2021HC WainwrightInitiated CoverageBuy$300.00
8/13/2021Credit Suisse GroupLower TargetOutperform$360.00 ➝ $324.00
7/2/2021CowenReiterated RatingBuy
4/20/2021William BlairInitiated CoverageOutperform
4/20/2021Jefferies Financial GroupInitiated CoverageBuy
4/20/2021Credit Suisse GroupInitiated CoverageOutperform$360.00
(Data available from 12/4/2020 forward)

News Sentiment Rating

0.35 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/8/2025
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/7/2025
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/7/2025
  • 7 very positive mentions
  • 13 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/6/2025
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/5/2025
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/5/2025
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/4/2025
  • 2 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/4/2025

Current Sentiment

  • 2 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

ImageneBio logo
ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc. and changed its name to ImageneBio, Inc. in July 2025. ImageneBio, Inc. is headquartered in San Diego, California.
Read More

Today's Range

Now: $6.78
Low: $6.59
High: $7.07

50 Day Range

MA: $7.82
Low: $6.21
High: $8.79

52 Week Range

Now: $6.78
Low: $6.19
High: $23.28

Volume

71,806 shs

Average Volume

45,412 shs

Market Capitalization

$75.80 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.44

Frequently Asked Questions

What sell-side analysts currently cover shares of ImageneBio?

The following equities research analysts have issued stock ratings on ImageneBio in the last year: Leerink Partners, Leerink Partnrs, Wall Street Zen, Wedbush, Weiss Ratings, and Zacks Research.
View the latest analyst ratings for IMA.

What is the current price target for ImageneBio?

0 Wall Street analysts have set twelve-month price targets for ImageneBio in the last year. Their average twelve-month price target is $26.50, suggesting a possible upside of 290.9%. Leerink Partners has the highest price target set, predicting IMA will reach $30.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $23.00 for ImageneBio in the next year.
View the latest price targets for IMA.

What is the current consensus analyst rating for ImageneBio?

ImageneBio currently has 2 sell ratings, 1 hold rating, 1 buy rating and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in IMA, but not buy more shares or sell existing shares.
View the latest ratings for IMA.

What other companies compete with ImageneBio?

Other companies that are similar to ImageneBio include Palisade Bio, Prima BioMed, Cellectis, Adherex Technologies and Larimar Therapeutics. Learn More about companies similar to ImageneBio.

How do I contact ImageneBio's investor relations team?

ImageneBio's physical mailing address is 645 SUMMER STREET SUITE 101, BOSTON MA, 02210. The company's listed phone number is 857-273-8343 and its investor relations email address is [email protected]. The official website for ImageneBio is ikenaoncology.com. Learn More about contacing ImageneBio investor relations.